Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled dose-exploration study of HN0037 tablets in recurrent genital herpes
CTR20252614Phase 2Completed
- Sponsor
- Huinno Biotech
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HN0037 in genital herpes, herpes simplex (HSV), sponsored by Huinno Biotech. Started Aug 2025; status: completed.
02
Drugs
HN0037
03
Conditions
genital herpesherpes simplex (HSV)
Beyond the preview
Go deeper on CTR20252614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252614.